AI assistant
LEAP THERAPEUTICS, INC. — Director's Dealing 2021
Sep 11, 2021
35080_dirs_2021-09-10_dbd16233-39e5-4a9b-87cc-4b5916e07a97.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LEAP THERAPEUTICS, INC. (LPTX)
CIK: 0001509745
Period of Report: 2021-09-08
Reporting Person: Bertagnolli Monica (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-08 | Stock Option (Right to Buy) | $1.58 | A | 65000 | Acquired | 2031-09-07 | Common Stock (65000) | Direct |
| 2021-09-08 | Stock Option (Right to Buy) | $1.58 | A | 16150 | Acquired | 2031-09-07 | Common Stock (16150) | Direct |
Footnotes
F1: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of September 8, 2021, the Vesting Start Date.
F2: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable with respect to 50% of the Option on September 30, 2021, and with respect to the remaining 50% of the Option on December 31, 2021.